The contemporary role of surgery in kidney cancer

J.B. Lattouf MD, Q.D. Trinh MD, and F. Saad MD

ABSTRACT

The diagnosis and treatment of renal cell carcinoma (RCC) has been the subject of major changes since the late 1980s. Initially, surgery was the only treatment available, but more recently, systemic therapies have been developed, and their introduction has modified some of the surgical indications for RCC. In addition, refinements in surgical technique and the introduction of minimally invasive approaches have revolutionized patient care and bear the promise of even more improvements to come. This paper provides an up-to-date overview of recent developments in the surgical treatment of RCC.

KEY WORDS

Kidney cancer, surgery, laparoscopy, minimally invasive technique

1. INTRODUCTION

Until recently, renal cell carcinoma (RCC) was considered mainly a surgical disease, because it is, by and large, one of the most chemo- and radioresistant tumours. Since the first nephrectomy was performed for neoplastic disease by Langenbuch in 1877, huge strides have been made in refining the surgical indications and technical aspects of surgery for RCC. During the quarter century since the mid-1980s, new imaging modalities such as ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) have come into widespread use. These diagnostic tests now allow for better preoperative staging and surgical planning of interventions. On the other hand, during that same period, imaging has also shifted the stage at which RCC is being diagnosed and treated, and now a question arises: Is surgical treatment still indicated for very small renal lesions 2-4, which in many cases are turning out to have an indolent natural history? At the other end of the spectrum, patients suffering from advanced-stage RCC have benefited from the introduction of systemic immune therapy, with some having complete and durable responses 5.

Surgical treatment retains its place in this setting in the form of cytoreductive nephrectomy 6,7. Further, the discovery of the von Hippel–Lindau (VHL) gene and the understanding gained of the molecular biology of the disease have set the stage for an exciting new era of targeted therapies 8. However, the role of cytoreductive nephrectomy with the new tyrosine kinase inhibitors (TKIs) remains to be defined.

The present review touches on the indications and controversies surrounding surgical treatments for RCC. The evolution of surgical techniques and the introduction of laparoscopy are also discussed.

2. SURGICAL TREATMENT FOR LOCALIZED RCC

2.1 Radical Nephrectomy

In 1963, Robson and colleagues published the seminal work that laid the foundations of surgical treatment for RCC as we know it today 9,10. Key surgical steps in achieving adequate and safe oncologic control were identified, including early vascular control and renal excision preserving Gerota’s fascia, thus ensuring that surgical margins are away from the tumour. Other concepts put forward by Robson included adrenal gland excision within Gerota’s fascia and extended ipsilateral lymphadenectomy from the crus of the diaphragm to the bifurcation of the aorta. These latter practices are not universally applied in the contemporary surgical approach, mostly because of a stage shift in RCC toward localized disease and because of the new imaging modalities. Nonetheless, the description of a radical nephrectomy remains one of the pillars of the treatment of localized RCC; all technical refinements developed thereafter have been guided by its basic principles.

Contemporary treatment of RCC is a factor of tumour size and location, presence of venous thrombus, and patient characteristics. Many incisions have been described, including flank, subcostal, midline, and thoraco-abdominal. Long-term oncologic results for open radical nephrectomy have been consistently reproduced and serve as a benchmark for other surgical
modalities. Although results from the initial series by Robson et al. showed a 5-year survival of 66% in localized disease \(^{10}\), outcomes improved significantly in later studies. For patients with stage I disease, 5-year survival in contemporary series is now established at 74%–95% \(^{11–15}\). Table 1 shows contemporary 5- and 10-year survival data after radical nephrectomy.

### 2.1.1 Role of Adrenalectomy

The incidence of adrenal metastasis from RCC in contemporary series has been reported at 2.7%–5.7% \(^{16–19}\). This low occurrence, coupled with modern imaging modalities, has led to many questions about the role of systematic adrenalectomy during radical nephrectomy as initially suggested by Robson. Motivations for adrenal sparing include the possibility of relapse in the contralateral adrenal, the potential for hormone imbalances, and the desire to achieve shorter operative times. Indications for adrenalectomy vary according to author and include large tumours, upper pole tumours, and adrenal anomalies noted on preoperative imaging or intraoperatively \(^{20}\).

In a large contemporary European series of 1179 nephrectomies, Antonelli et al. found no adrenal metastases associated with tumours under 4 cm. Tumour location within the kidney was not predictive of adrenal involvement, and imaging by CT had a low sensitivity at 47%. Thus, the authors suggested the ipsilateral adrenal be spared only for tumours smaller than 4 cm, independent of tumour location, provided that preoperative imaging of the adrenal gland is normal \(^{18}\). Another study by Siemer et al., also with a large sample (n = 1010), arrived at the same conclusions, underlining the importance of the 4-cm cut-off and the irrelevance of tumour location \(^{21}\). It therefore seems prudent to consider clinical stage as the sole indication for adrenalectomy when radical nephrectomy is considered.

### 2.1.2 Role of Lymphadenectomy

Until recently, the role of lymphadenectomy in RCC surgery was a subject of controversy. Although the incidence of lymph node metastases as initially published by Robson et al. was 30%, modern series report occult metastases in only 3.3% of cases \(^{10,22}\). However, even if lymphadenectomy may provide for accurate staging with no increased morbidity, its benefit with respect to survival and disease progression has not been established. A retrospective study of RCC surgical patients in the U.S. Surveillance, Epidemiology, and End Results database between 1983 and 1998 showed no survival advantage when extensive lymphadenectomy was performed in localized disease \(^{23}\). Furthermore, the published results of the randomized phase III European Organization for Research and Treatment of Cancer (EORTC) 30881 trial assessing radical nephrectomy with and without lymphadenectomy confirm the lack of a survival difference associated with the added lymph node dissection \(^{24}\). However, the value of lymphadenectomy in clinically node-positive patients undergoing cytoreductive nephrectomy for advanced disease remains to be clarified \(^{25}\).

### 2.1.3 Surgery with Venous Thrombus

One particular challenge in RCC surgery is macroscopic tumour extension into the venous system, namely the vena cava, which occurs in 5%–10% of cases \(^{26}\). When RCC is still localized in such a setting, surgery remains the mainstay of treatment \(^{27,28}\). The largest series published to date on venous tumoural extension relates a multicentric experience from Europe, regrouping 1192 patients operated on between 1982 and 2003 \(^{29}\). The authors reported median survivals of 52 months for thrombi limited to the renal vein, 25.8 months for thrombi in the subdiaphragmatic vena cava, and 18 months for thrombi above the vena cava. A difference in survival was detected between tumours in the renal vein and those in the vena cava. However, the level of the tumour thrombus in the vena cava did not significantly affect survival.

The foregoing findings are very similar to results from the largest single-centre experience published to date from the Mayo clinic, where the 5-year survival was 49.1% for tumours limited to the renal vein and 26.3%–39.4% for tumours in the vena cava \(^{30}\). This last study—and others—also found statistically different survivals for renal vein as compared with vena cava thrombi, but the level of the thrombus in the vena cava was not predictive of survival \(^{31}\). It seems, in fact, that biologic aggressiveness in such settings is dictated mainly by tumour grade and not

| Reference                  | 5-Year Survival (%) | 10-Year Survival (%) |
|----------------------------|---------------------|----------------------|
|                            | I      | II     | III    | IV     | I    | II    | III    | IV    |
| Kinouchi et al., 1999 \(^{11}\) | 99    | 92    | 70    | 24    | 93   | 73    | 49    | 19    |
| Guinan et al., 1995 \(^{12}\) | 65    | 51    | —     | —     | —    | —     | —     | —     |
| Javidan et al., 1999 \(^{13}\) | 95    | 88    | 59    | 20    | 96   | 92    | 43    | 14    |
| Tsui et al., 2000 \(^{14}\) | 83    | 57    | 42    | 28    | —    | —     | —     | —     |
| Gettman et al., 2001 \(^{15}\) | 99    | 90    | 66    | 39    | 97   | 84    | 53    | 32    |
Laparoscopic radical nephrectomy was first described for neoplastic disease by Clayman et al. in 1991. The many interesting advantages, including a lesser postoperative analgesia requirement, shorter hospital stay, quicker convalescence, and improved cosmesis, have fuelled enthusiasm for this new approach and made it the preferred modality for localized RCC. Oncologic outcomes have been published with medium- and long-term follow-up (Table II), and comparative studies show equivalence of laparoscopic radical nephrectomy and the open approach.

Laparoscopy has been applied successfully to renal tumours as large as 16 cm—albeit follow-up for this patient population is still limited, and few publications are available. Furthermore, laparoscopic radical nephrectomy is feasible in the overweight patient, and although technically more challenging, this approach may result in superior perioperative outcomes as compared with the open technique. Finally, centres of expertise have reported laparoscopic nephrectomies with renal vein and vena cava tumour thrombi, confirming the safety and feasibility of the technique. In the view of many experts in the field, laparoscopic radical nephrectomy should be the standard of care for localized RCC whenever technically feasible and when a partial nephrectomy is not indicated.

Access to the kidney may be obtained in a trans- or retroperitoneal fashion, with each route having its advantages and drawbacks. The retroperitoneal approach provides faster access to the renal hilum and may be the best choice for patients with posterior tumours or with multiple prior abdominal surgeries. The transperitoneal approach remains the most popular, however, because it affords a larger working space and more familiar anatomic landmarks. Notwithstanding these differences, both approaches seem to be equivalent in terms of perioperative outcome.

To ease the learning curve, hand-assisted laparoscopic radical nephrectomy (HALRN) was developed in parallel with the pure laparoscopic approach. It consists of taking advantage of the incision from which the specimen is to be extracted to position a hand-assist device that allows for the infra-abdominal introduction of the operator’s hand. This technique offers the added advantage of tactile feedback and allows for manual compression when brisk bleeding is encountered. Although pure laparoscopic nephrectomy, as compared with HALRN, may show a trend toward fewer complications in high-risk patients (American Society of Anesthesiologists score ≥3), the HALRN approach was shown to be equivalent to open radical nephrectomy on long-term follow-up.

### Table II: Laparoscopic radical nephrectomy for T1–2 disease: overall survival with medium- and long-term follow-up

| Reference                  | 5-Year Cancer-Specific/Overall (%) | 10-Year  |
|----------------------------|-----------------------------------|---------|
| Chan et al., 2001          | 85 / —                            | —       |
| Hemal et al., 2007         | 88 / 85.6                          | —       |
| Ono et al., 1999           | 95 / —                             | —       |
| Permpongkosol et al., 2005 | 97 / 85                           | 97 / 76 |
| Saika et al., 2003         | 94                                | —       |
| Portis et al., 2002        | 98 / 81                           | —       |
2.2.1 Open NSS
Studies on open NSS with a normal contralateral kidney have shown that, for tumours under 4 cm in size, oncologic control in terms of 5- and 10-year survival is equivalent to that seen with radical nephrectomy. Partial nephrectomy has been attempted for larger tumours, but follow-up of these patients in the literature is scarce. Overall, NSS is not associated with more complications than is radical nephrectomy. It is thus widely accepted that partial nephrectomy constitutes the “gold standard” for the treatment of localized RCC smaller than 4 cm.

The EORTC 30904 randomized controlled study, whose objective was to compare NSS with radical nephrectomy, has been completed. The results with regard to oncologic outcomes are awaited with great anticipation.

2.2.2 Laparoscopic NSS
Because of the complex technical steps involved in partial nephrectomy, the laparoscopic approach to this procedure was slow to emerge as a viable alternative. One of the main initial hurdles to overcome was hemostasis after parenchymal incision, and initial laparoscopic NSS procedures were performed mainly for small exophytic renal lesions with very little parenchymal involvement. With evolving experience, intracorporeal knot-tying and hilar clamping emulating the open approach came into use, and the treatment of intraparenchymal lesions became feasible. Because of prolonged warm ischemia times at first, novel and innovative methods of cold ischemia have been described with varying degrees of success and varying advantages and caveats. These methods have included ice-slush cooling, intra-arterial cold saline perfusion, and collecting system cold perfusion using a ureteral catheter. However, renal cooling is less frequently used now, because clamping times have been significantly reduced with evolving experience.

Medium-term follow-up of oncologic outcomes with laparoscopic NSS for small renal tumours is becoming available. The data reveal excellent results that are comparable to those achieved with the open approach. Increasingly larger and more complex tumours are being managed using laparoscopic NSS. However, because of the complexity of the procedure and the paucity of long-term follow-up data, laparoscopic NSS remains an approach under investigation that should be performed only in centres with the requisite experience.

2.2.3 Robotic NSS
Tele-robotic surgical systems have recently been introduced with the main goal of reducing the complexity of intracorporeal suturing, often at difficult angles, as compared with conventional laparoscopy. Gettman et al. first described robot-assisted laparoscopic partial nephrectomy (RALPN) in 2004. In the initial report of 13 cases by these authors, mean lesion size was 3.5 cm (range: 2.0–6.0 cm), mean operative time was 215 minutes (range: 130–262 minutes), and mean blood loss was 170 mL (range: 50–300 mL). Positive margins were reported in 1 case (7.7%). The conclusion was that RALPN is technically feasible and safe. One concern was the potential for delayed intervention in situations of urgent conversion such as massive hemorrhage. Nevertheless, other groups have reported the feasibility and safety of RALPN. Interestingly, Aron et al. published a matched-pair series that compared the experience between robotic and laparoscopic partial nephrectomy at the Cleveland Clinic. Overall, no differences were observed in perioperative variables (warm ischemia time, estimated blood loss, surgery time, length of stay). Fewer ports were used during laparoscopy. Renal functional outcomes, transfusion rate, and complication rates were comparable. Two RALPN cases required conversion to standard laparoscopy. The authors concluded that RALPN is a developing procedure and that further experience is necessary to determine the relative merits of RALPN. At the date of writing, oncologic outcomes are yet to be determined, but RALPN is not likely to improve surgical and oncologic outcomes over laparoscopy. It might, however, permit more urologists to perform this complex procedure, allowing it to evolve into mainstream practice.

3. SURGICAL TREATMENT FOR METASTATIC RCC

3.1 Cytoreductive Nephrectomy

The rationale of cytoreductive nephrectomy in metastatic RCC is twofold: first, to remove a large tumour burden that could theoretically be immunosuppressive, and second, to prevent potential local complications in the course of systemic therapy. Systemic therapy for RCC has evolved over the past 20 years from immune-based agents such as interferon alfa and interleukin-2, to the most recent small-molecule inhibitors, including sorafenib, sunitinib, and temsirolimus. In the setting of systemic immunotherapy, cytoreductive nephrectomy may be performed before treatment and has been shown to prolong survival in Southwest Oncology Group (SWOG) and EORTC trials using interferon alfa. However, nephrectomy before immunotherapy has the caveat, in up to 60% of patients, of possible complications that may preclude these patients from ever receiving immunotherapy. Some investigators have therefore sought to assess systemic therapy as first-line therapy so as to delineate responders, considering them to be the only candidates likely to benefit from subsequent surgery. Using this paradigm, the 31%–50% of patients who are non-responders are spared the morbidity of nephrectomy.
The laparoscopic approach to cytoreductive nephrectomy offers the advantage of reduced recovery time and perhaps the opportunity to initiate systemic therapy earlier than might occur with the open approach. Laparoscopic nephrectomy has been assessed, and Walthers et al. from the National Cancer Institute published a series in which the technique was shown to be safe and feasible.

In the era of TKIs, the role of cytoreductive nephrectomy is not clearly defined. A discussion of the various trials pertaining to TKI therapy for RCC is beyond the scope of this review, and yet it should be emphasized that most patients assigned to treatment with a TKI in randomized trials had already undergone nephrectomy. Thus, to remain comparable with the experimental setup, it seems reasonable to proceed to surgical cytoreduction in properly selected patients in the clinical setting.

3.2 Metastasectomy

Few studies are available on the effects of metastasectomy, whether used alone or in combination with systemic therapy. It is commonly accepted that a better prognosis follows from resection of lung metastases than from extrapulmonary lesions. Patients with synchronous metastases fare worse than do those with metachronous metastases. Furthermore, the longer the time from primary tumour resection to metastasectomy, the better the chances of achieving cure. The number of resectable metastases and the number of re-resections do not seem to affect the overall prognosis. Finally, a resection with the goal of achieving curative oncologic control results in far better survival than does palliative resection only. A retrospective study from the MD Anderson Cancer Center showed that, when it comes to exclusively local recurrence, surgery plus systemic therapy portends a 5-year survival of 50%, which is significantly superior to the survival seen with surgical resection alone.

4. CONCLUSIONS

The surgical treatment of RCC has evolved tremendously since the end of the 1980s. It remains the most efficient modality to cure localized disease, and it is the “gold standard” by which newer, minimally invasive therapies should be assessed. With the advent of new systemic therapies for RCC, many questions have been raised that remain to be answered concerning the role and timing of surgical cytoreduction. As with all other fields in oncology, the future of RCC surgery lies in identifying the patients that will eventually benefit the most from surgical treatment and in sparing those that will not. The ultimate answers will probably come from the discovery of novel biomarkers, resulting in genetically tailored treatment for each individual patient.

5. ACKNOWLEDGMENTS

The authors thank Les Urologues Associés du CHUM.

6. REFERENCES

1. Langenbuch CJA. Nephrectomy for malignant disease [German]. Berl Klin Wochenschr 1877;14:337–40.
2. Rendon RA, Jewett MAS. Expectant management for the treatment of small renal masses. Urol Oncol 2006;24:62–7.
3. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006;175:425–31.
4. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331–4.
5. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008;113:293–301.
6. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655–9.
7. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon alfa-2b compared with interferon alfa-2b alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–70.
8. Escudier B, Eisen T, Stadler WM, et al. on behalf of the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.
9. Robson CJ. Radical nephrectomy for renal cell carcinoma. J Urol 1963;89:37–42.
10. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297–301.
11. Kinouchi T, Saiki S, Meguro N, et al. Impact of tumor size on the clinical outcomes of patients with Robson stage I renal cell carcinoma. Cancer 1999;85:689–95.
12. Guinan PD, Vogelzang NJ, Fremgen AM, et al. Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee. J Urol 1995;153:901–3.
13. Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999;162:1277–81.
14. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Beldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163:1090–5.
15. Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001;91:354–61.
SURGERY IN RENAL CELL CARCINOMA

16. Sawai Y, Kinouchi T, Mano M, et al. Ipsilateral adrenal involvement from renal cell carcinoma: retrospective study of the predictive value of computed tomography. *Urology* 2002;59:28–31.

17. Paul R, Mordhorst J, Busch R, Leyh H, Hartung R. Adrenal sparing surgery during radical nephrectomy in patients with renal cell cancer: a new algorithm. *J Urol* 2001;166:59–62.

18. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. *Cancer* 2004;100:738–45.

19. Tsui KH, Shvarts O, Barbaric Z, Figlin R, de Kernion JB, Belldegrun A. Is adrenalectomy a necessary component of radical nephrectomy? *UCLA* experience with 511 radical nephrectomies. *J Urol* 2000;163:437–41.

20. Autorino R, Di Lorenzo G, Damiano R, et al. Adrenal sparing surgery in the treatment of renal cell carcinoma: when is it possible? *World J Urol* 2003;21:153–8.

21. Siemer S, Lehmann J, Kamradt J, et al. Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. *J Urol* 2004;171:2155–9.

22. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the *EORTC* randomized phase III protocol 30881. *EORTC* Genitourinary Group. *Eur Urol* 1999;36:570–5.

23. Joslyn SA, Sirintrapun SJ, Konety BR. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. *Urology* 2005;65:675–80.

24. Blom JH, van Poppel H, Marechal JM, et al. on behalf of the *EORTC* Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (*EORTC*) randomized phase 3 trial 30881. *Eur Urol* 2009;55:28–34.

25. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. *J Urol* 2003;169:2076–83.

26. Oto A, Herts BR, Remer EM, Novick AC. Inferior vena cava tumor thrombus in renal cell carcinoma: staging by MR imaging and impact on surgical treatment. *Am J Roentgenol* 1998;171:1619–24.

27. Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. *J Urol* 1996;155:448–50.

28. Parekh DJ, Cookson MS, Chapman W, et al. Renal cell carcinoma with renal vein and inferior vena cava caval involvement: clinicopathological features, surgical techniques and outcomes. *J Urol* 2005;173:1897–902.

29. Wagner B, Patard JJ, Mjean A, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. *Eur Urol* 2008;[Epub ahead of print].

30. Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumor thrombus. *BJU Int* 2004;94:33–41.

31. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? *J Urol* 2004;171:598–601.

32. Terakawa T, Miyake H, Takenaka A, Hara I, Fujisawa M. Clinical outcome of surgical management for patients with renal cell carcinoma involving the inferior vena cava. *Int J Urol* 2007;14:781–4.

33. Ciancio G, Soloway MS. Renal cell carcinoma with tumor thrombus extending above diaphragm: avoiding cardiopulmonary bypass. *Urology* 2005;66:266–70.

34. Ciancio G, Livingstone AS, Soloway M. Surgical management of renal cell carcinoma with tumor thrombus in the renal and inferior vena cava: the University of Miami experience in using liver transplantation techniques. *Eur Urol* 2007;51:988–95.

35. Clayman RV, Kavoussi LR, Soper NJ, et al. Laparoscopic nephrectomy. *N Engl J Med* 1991;324:1370–1.

36. Cadeddu JA, Ono Y, Clayman RV, et al. Laparoscopic nephrectomy for renal cell cancer: evaluation of efficacy and safety: a multicenter experience. *Urology* 1998;52:773–7.

37. Chan DY, Cadeddu JA, Jarrett TW, Marshall FF, Kavoussi LR. Laparoscopic radical nephrectomy: cancer control for renal cell carcinoma. *J Urol* 2001;166:2095–100.

38. Hemal AK, Kumar A, Gupta NP, Kumar R. Oncologic outcome of 132 cases of laparoscopic radical nephrectomy with intact specimen removal for T1–2N0M0 renal cell carcinoma. *World J Urol* 2007;25:619–26.

39. Ono Y, Kinukawa T, Hattori R, et al. Laparoscopic radical nephrectomy for renal cell carcinoma: a five-year experience. *Urology* 1999;53:280–6.

40. Permpongkosol S, Chan DY, Link RE, et al. Long-term survival analysis after laparoscopic radical nephrectomy. *J Urol* 2005;174:1222–5.

41. Saika T, Ono Y, Hattori R, et al. Long-term outcome of laparoscopic radical nephrectomy for pathologic T1 renal cell carcinoma. *Urology* 2003;62:1018–23.

42. Portis AJ, Yan Y, Landman J, et al. Long-term followup after laparoscopic radical nephrectomy. *J Urol* 2002;167:1257–62.

43. Hemal AK, Kumar A, Kumar R, Wadhwa P, Seth A, Gupta NP. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. *J Urol* 2007;177:862–6.

44. Abbou CC, Cicco A, Gasman D, et al. Retroperitoneal laparoscopic versus open radical nephrectomy. *J Urol* 1999;161:1776–80.

45. Dunn MD, Portis AJ, Shalhav AL, et al. Laparoscopic versus open radical nephrectomy: a 9-year experience. *J Urol* 2000;164:1153–9.

46. Steinberg AP, Finelli A, Desai MM, et al. Laparoscopic radical nephrectomy for large (greater than 7 cm, T2) renal tumors: a long-term prospective comparison. *J Urol* 2004;172:2172–6.

47. Feder MT, Patel MB, Melman A, Ghavamian R, Hoenig DM. Comparison of open and laparoscopic nephrectomy in obese and nonobese patients: outcomes stratified by body mass index. *J Urol* 2008;180:79–83.

48. Martin GL, Castle EP, Martin AD, et al. Outcomes of laparoscopic radical nephrectomy in the setting of vena caval and renal vein thrombus: seven-year experience. *J Endourol* 2008;22:1681–6.

49. Romero FR, Muntener M, Bagga HS, Brito FA, Sultan A, Jarrett TW. Pure laparoscopic radical nephrectomy with level II vena cava thrombectomy. *Urology* 2006;68:1112–14.
50. Kapoor A, Nguan C, Al-Shaiji TF, et al. Laparoscopic management of advanced renal cell carcinoma with level I renal vein thrombus. *Urolology* 2006;68:514–17.

51. Desai MM, Strzempekowski B, Matin SF, et al. Prospective randomized comparison of transtperitoneal versus retroperitoneal laparoscopic radical nephrectomy. *J Urol* 2003;170:38–41.

52. Baldwin DD, Dunbar JA, Parekh DJ, et al. Single-center comparison of purely laparoscopic, hand-assisted laparoscopic, and open radical nephrectomy in patients at high anesthetic risk. *J Endourol* 2003;17:161–7.

53. Chung SD, Huang KH, Lai MK, et al. Long-term follow-up of hand-assisted laparoscopic radical nephrectomy for organ-confined renal cell carcinoma. *Urolology* 2007;69:652–5.

54. Chow WH, Devesa SS, Warren JL, Fraumeni Jr. Rising incidence of renal cell cancer in the United States. *JAMA* 1999;281:1628–31.

55. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. *Urolology* 1998;51:203–5.

56. McKiernan J, Yossepowitch O, Kattan MW, et al. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. *Urolology* 2002;60:1003–9.

57. Snyder ME, Bach A, Kattan MW, Raj GV, Reuter VE, Russo P. Incidence of benign lesions for clinically localized renal cell carcinoma with a normal contralateral kidney: 10-year followup. *Nat Clin Pract Urol* 2006;3:575–84.

58. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. *Lancet* 1992;340:807–10.

59. Bijol V, Mendez GP, Hurwitz S, Rennke HG, Névé E. Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens: predicting the risk of progressive renal failure. *Am J Surg Pathol* 2006;30:575–84.

60. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. *Mayo Clin Proc* 2000;75:1236–42.

61. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. *Urolology* 2002;59:816–20.

62. Patel MI, Simmons R, Kattan MW, Motzer RJ, Reuter VE, Russo P. Long-term follow-up of bilateral sporadic renal tumors. *Urolology* 2003;61:921–5.

63. Rabbani F, Herr HW, Almahmeed T, Russo P. Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. *J Clin Oncol* 2002;20:2370–5.

64. Lam JS, Bergman J, Breda A, Schulam PG. Importance of surgical margins in the management of renal cell carcinoma. *Nat Clin Pract Urol* 2008;5:308–17.

65. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. *J Urol* 1999;162:1930–3.

66. Herr HW. Partial nephrectomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. *J Urol* 1999;161:33–5.

67. Krejci KG, Blute ML, Cheville JC, Sebo TJ, Lohse CM, Zincke H. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome. *Urolology* 2003;62:641–6.

68. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm or less in a contemporary cohort. *J Urol* 2000;163:730–6.

69. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. *J Urol* 2004;171:1066–70.

70. Becker F, Siemer S, Hack M, Humke U, Ziegler M, Stöckle M. Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm. *Eur Urol* 2006;49:1058–64.

71. Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. *Urolology* 2006;67:260–4.

72. Dash A, Vickers AJ, Schachter LR, Bach AM, Snyder ME, Russo P. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm. *BJU Int* 2006;97:939–45.

73. Stephenson AJ, Hakimi AA, Snyder ME, Russo P. Complications of radical and partial nephrectomy in a large contemporary cohort. *J Urol* 2004;171:130–4.

74. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? *J Urol* 2009;181:55–62.

75. Thompson RH, Leibovich BC, Lohse CM, Zincke H, Blute ML. Complications of contemporary open nephron sparing surgery: a single institution experience. *J Urol* 2005;174:855–8.

76. Van Poppel H, Da Pozzo L, Albrecht W, et al. on behalf of the European Organization for Research and Treatment of Cancer (EORTC); National Cancer Institute of Canada Clinical Trials Group (NCIC CTG); Southwest Oncology Group (SWOG); and Eastern Cooperative Oncology Group (ECOG). A prospective randomized EORTC Intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol* 2007;51:1606–15.

77. Gill IS, Desai MM, Kaouk JH, et al. Laparoscopic partial nephrectomy for renal tumor: duplicating open surgical techniques. *J Urol* 2002;167:469–76.

78. Gill IS, Abreu SC, Desai MM, et al. Laparoscopic ice slush renal hypothermia for partial nephrectomy: the initial experience. *J Urol* 2003;170:52–6.

79. Crispen PL, Boorjian SA, Lohse CM, et al. Outcomes following partial nephrectomy by tumor size. *J Urol* 2008;180:1912–17.

80. Janetschek G, Abdelmaksoud A, Bagheri F, Al-Zahrani H, Leeb K, Gschwandtner M. Laparoscopic partial nephrectomy in cold ischemia: renal artery perfusion. *J Urol* 2004;171:68–71.

81. Landman J, Venkatesh R, Lee D, et al. Renal hypothermia achieved by retrograde endoscopic cold saline perfusion: technique and initial clinical application. *Urolology* 2003;61:1023–5.

82. Lane BR, Gill IS. 5-Year outcomes of laparoscopic partial nephrectomy. *J Urol* 2007;177:70–4.

83. Haber GP, Gill IS. Laparoscopic partial nephrectomy: contemporary technique and outcomes. *Eur Urol* 2006;49:660–5.

84. Ukimura O, Haber GP, Remer EM, Gill IS. Laparoscopic partial nephrectomy for incidental stage T2 or worse tumors. *Urolology* 2006;68:976–82.
85. Lattouf JB, Beri A, D’Ambros OF, Grull M, Leeb K, Janetschek G. Laparoscopic partial nephrectomy for hilar tumors: technique and results. *Eur Urol* 2008;54:409–18.

86. Gittman MT, Blute ML, Chow GK, Neururer R, Bartsch G, Peschel R. Robotic-aided laparoscopic partial nephrectomy: technique and initial clinical experience with da Vinci robotic system. *Urology* 2004;64:914–18.

87. Phillips CK, Taneja SS, Stifelman MD. Robot-assisted laparoscopic partial nephrectomy: the NYU technique. *J Endourol* 2005;19:441–5.

88. Caruso RP, Phillips CK, Kau E, Taneja SS, Stifelman MD. Robot assisted laparoscopic partial nephrectomy: initial experience. *J Urol* 2006;176:36–9.

89. Kaul S, Laungani R, Sarle R, *et al.* da Vinci-assisted robotic partial nephrectomy: initial experience. *BJU Int* 2008;102:86–92.

90. Rogers CG, Singh A, Blatt AM, Linehan WM, Pinto PA. Robotic partial nephrectomy for complex renal tumors: surgical technique. *Eur Urol* 2008;53:514–21.

91. Aron M, Koenig P, Kaouk JH, Nguyen MM, Desai MM, Gill IS. Robotic and laparoscopic partial nephrectomy: a matched-pair comparison from a high-volume centre. *BJU Int* 2008;102:86–92.

92. Ho H, Schwentner C, Neururer R, Steiner H, Bartsch G, Peschel R. Robot-assisted laparoscopic partial nephrectomy: surgical technique and clinical outcomes at 1 year. *BJU Int* 2008;[Epub ahead of print].

93. Wang AJ, Bhayani SB. Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: single-surgeon analysis of >100 consecutive procedures. *Urology* 2008;[Epub ahead of print].

94. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J Urol* 2004;171:1071–6.

95. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. *J Urol* 1995;154:32–4.

96. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. *J Urol* 1997;158:1675–8.

97. Walther MM, Alexander RB, Weiss GH, *et al.* Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. *Urology* 1993;42:250–7.

98. Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, de Gast GC. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. *Eur Urol* 2006;49:76–81.

99. Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor *in situ*. *Eur Urol* 2002;42:570–6.

100. Walther MM, Lyne JC, Libutti SK, Linehan WM. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. *Urology* 1999;53:496–501.

101. Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. *Arch Surg* 1992;127:1343–9.

102. Sherry RM, Pass HI, Rosenberg SA, Yang JC. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. *Cancer* 1992;69:1850–5.

103. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. *Eur Urol* 1999;35:197–203.

104. Tanguay S, Pisters LL, Lawrence DD, Dinney CP. Therapy of locally recurrent renal cell carcinoma after nephrectomy. *J Urol* 1996;155:26–9.

**Correspondence to:** Jean-Baptiste Lattouf, Department of Surgery–Urology, Centre Hospitalier de l’Université de Montréal, 1058 rue St-Denis, Montreal, Quebec H2X 3J4.

**E-mail:** jean-baptiste.lattouf@umontreal.ca